Indication: Diffuse Large B-cell Lymphoma (DLBCL)
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL
Relapsed or Refractory
Line of Therapy: 2nd or 3rd line
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Molecular Templates, Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org